Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
The Asia Pacific defibrillators market has the potential to reach $ 4,734.4 million by 2022. The Asia-Pacific region would be the most lucrative of the region, for the defibrillators market, and the region is expected to be the fastest-growing market during the forecast period. The growth in the region can be attributed to facts such as the growing demand for sophisticated defibrillators, major healthcare reforms, the high prevalence of heart failures, and the growing demand for technologically advanced cost-effective defibrillators.
Nevertheless, factors such as weak reimbursement policies for defibrillation procedures, under equipped healthcare infrastructure, limited awareness among physicians & patients about different treatment devices, and high cost of the devices would Challenge the market growth. The report highlights the adoption of Defibrillators in Asia Pacific.
Based on the product type; the Defibrillators market is segmented into Advanced Life Support (ALS) Defibrillators, Automated External Defibrillators (AEDs), Implantable Cardioverter Defibrillators (ICD), Wearable Defibrillators market. Further the Implantable Cardioverter Defibrillators (ICD) segment is sub segmented into Transvenous Implantable Cardioverter Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs) market.
Based on the end use avenue, the market is bifurcated into Hospitals, Pre-hospitals, Public Access Markets, Alternate Care Markets, Home Healthcare market. The countries included in the report are Germany, UK, France, Russia, Spain, Italy and Rest of Europe.
The report provides a comprehensive analysis of the key players operating in the world defibrillators market, such as Asahi Kasei Corporation, Stryker Corporation, Biotronik SE & Co. KG, Boston Scientific Corporation, Philips Healthcare, LivaNova PLC, Medtronic plc, Cardiac Science Corporation, Nihon Kohden Corporation, and St. Jude Medical, Inc.